According to CRI analysis, the global viral vector and plasmid DNA manufacturing market is expected to register a CAGR of ~16.9% from 2021 to 2027 and hold a value of ~USD 4,870 million in2027.
The global viral vector and plasmid DNA manufacturing market is driven by the rising demand for viral vector-based vaccines for infectious diseases and a shift in the treatment paradigm of several life-threatening diseases through advanced the rapies and technological advancements in viral vectors.
Several key players are dominating the global viral vector and plasmid DNA manufacturing market, contributing to a significant revenue share. The prominent players are involved in organic and inorganic strategies such as agreements, new product development & launches, mergers & acquisitions, joint ventures, collaborations, partnerships and geographic expansions, to sustain their market positions.For instance,in April 2021, Albumedix (UK) extended its research collaboration with Cobra Biologics (US) for the upstream and downstream processing of AAV and lentiviral vector. The collaboration was intended for stability enhancement and process optimization by the company.
Based on region, North America is expected to dominate the global viral vector and plasmid DNA manufacturing market in 2020. Factors such as the presence of a large number of centers and institutes engaged in the R&D of advanced therapies and key players in this region involved in new product launches, expansion, acquisition,and strategic collaborations are driving the market growth. For instance, In March 2021, ABECMA (idecabtagenevicleucel), a lentivirus-based gene therapy, received the US FDA approval to treat R/R multiple myeloma.
Europe is expected to hold the second-largest position in the global viral vector and plasmid DNA manufacturing market in 2021. Key factors attributing to the market growth are the increasing R&D spendings to enhance research activities in the healthcare industry. For instance, according to the data published in Eurostat in 2018, the EU spent approximately 348 USD million on Research & Development. The R&D expenditure as a percentage of GDP was 2.18% in 2018, compared to 1.87 % in 2008.
Asia-Pacific is anticipated to be the fastest-growing regional market over the assessment period due to the increasing prevalence of target disorders and healthcare needs. Furthermore, the growth of the market in the rest of the world is attributed to the rising penetration of advanced healthcare technologies in research organizations focused on viral vector and plasmid DNA manufacturing incountries such as Saudi Arabia and the UAE. Developing countries such as Argentina, Brazil, and Colombia, among others in Latin America, are also key contributors to the growth of the market.
The global viral vector and plasmid DNA manufacturing market has been segmented into vector type, workflow, disease type, application, and end user.
By vector type, the market is segmented into plasmid DNA, viral vector, non-viral vector. The viral vector segment represented the dominant share in 2020, owing to the rising prevalence of target diseases and disorders, the effectiveness of viral vectors in gene therapy delivery, and rising research activities focused on viral vector-based gene & cell therapies.
Based on the workflow, the market is segmented into upstream processing, downstream processing. Downstream processing dominated the market for viral vectors and plasmid DNA manufacturing in 2020. Increasing adoption of downstream processing methods to help reduce contaminants originating from host cells or culture media is driving the market growth of this segment.
On the basis of disease type, the market has been segmented into genetic disorders, cancer, infectious diseases, and others. Cancer held the largest market share in 2020 due to the increasing prevalence of cancer cases globally. Furthermore, genetic disorders are expected to be the fastest-growing segment.
Based on application, the market is segmented into antisense & RNAi therapy, gene therapy, cell therapy, vaccinology, and research. The vaccinology segment dominated the market in 2020, owing tothe rising adoption of viral vectors in vaccine development.
By end user, pharmaceutical & biopharmaceutical companies and research institutes. Research institutes held a major share in the global viral vectors and plasmid DNA manufacturing market. The increasing number of research centers in gene and cell therapy coupled with rising research activities for viral vectors and plasmid DNA is projected to increase the demand for viral vectors in the global market.
Global Radiation Therapy in the Oncology Market: Focus on Radiation Therapy Systems, Product Regulation, Key Strategies and Developments, Market Dynamics, 15 Company Profiles, and 12 Countries Data and Cross Segmentation – Analysis and Forecast, 2021-2031
Some of the key players in the global Viral Vector and Plasmid DNA Manufacturing market are Cognate BioServices, Inc. (US), Catalent Pharma Solutions (US), Fujifilm Holdings Corporation (Japan), Johnson & Johnson (US), Sanofi Corporation (France), F. Hoffmann-LA Roche Ltd (Switzerland), 4D Molecular Therapeutics (US), Sirion Biotech GmbH (Germany), Voyager Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Gene Therapy Catapult (UK), UniQure (Netherlands), MassBiologics (US), Renova Therapeutics (US) and Shenzhen SiBionoGeneTech Co., Ltd (China).